News | June 30, 2022
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
The settlement and dismissal resolves all claims between the parties
The settlement and dismissal resolves all claims between the parties
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
Medidata Detect and Rave CTMS Have Improved Study Execution Through Role-Based Monitoring Workflows and Clinical Data Visualization for Hundreds of Customers Across More Than 9,000 Studies
First and only PARP inhibitor to improve invasive disease-free survival in patients
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Subscribe To Our Newsletter & Stay Updated
